iclight,
Guess I added too much commentary on my first attempt to respond lol. So let’s try this again ; ). The point you are trying to make is made moot by the changes in the endpoints and SAP which take into consideration the fact that crossover patients from SOC, according to Dr Linda Liau’s comments you posted, are apparently living longer, possibly from treatment, which the revised SAP (perfectly acceptable the way done under the exceptions to adequate and well controlled trials guidance) and new endpoints are set to properly measure for both early treated and late (crossover) treated patients.
Of course by now this should no longer be necessary to explain but some folks just have a more difficult time understanding the real illumination granted by the revised endpoints being reviewed and posted by the Europeans, which of course the journal article is expected to grant peer reviewed validation to, which some posters don’t want because they have hounded the board with calls for early release of top line data reporting, which in and of itself is inadequate to explain the amount of benefit received by each group of patients, which then provides a basis for attack upon the results, which then would be followed up with an attack on share price, which would make it more difficult to negotiate for true value from any unsolicited buyout offer, which would create division amongst shareholders and an easy sell off at greatly discounted prices of derisked shares, which of course is exactly what some folks would like to see happen but it won’t because Linda is just too smart for them all by being willing to wait out the process even at the expense of investor expectations she helped create. So are you seeing the light now or being blinded by it?; ). Best wishes.
